Healthcare can be complicated.
Your cardiology news shouldn’t be.
Join thousands of cardiology leaders today.
Cardiology Pharmaceuticals May 15, 2025
Tirzepatide Beats Semaglutide in Weight Loss May 15, 2025
Has a king of the GLP-1s finally been crowned? Full results from the SURMOUNT-5 trial published in NEJM seem to suggest that Eli Lilly’s tirzepatide (Zepbound/Mounjarno) could be better than Novo Nordisk’s semaglutide (Wegovy/Ozempic). Weighing the weight loss benefits of each drug, SURMOUNT-5’s researchers randomized 751 obese patients without T2D to receive either tirzepatide (10mg/15mg) […]
Cardiology Testing May 12, 2025
Predicting ASCVD With Calprotectin May 12, 2025
Knowing which biomarkers to look for is critical to diagnosing and preventing ASCVD, and a new JAMA study suggests calprotectin could be the key to catching ASCVD early. So how does calprotectin predict ASCVD? To answer this, researchers measured calprotectin levels in plasma collected from 2.4k participants during Phase 2 of the Dallas Heart Study […]
Cardiology Pharmaceuticals May 8, 2025
Obicetrapib Puts on a Show May 8, 2025
Results from NewAmsterdam Pharma’s Phase 3 BROADWAY and TANDEM trials suggest that obicetrapib could be an effective LDL-C lowering treatment, both on its own or combined with another drug. TANDEM examined the effects of a fixed-dose obicetrapib/ezetimibe combination therapy and found… BROADWAY put on a one-man show for obicetrapib as a monotherapy to help confirm […]
Cardiology Pharmaceuticals May 8, 2025
Marea Makes Progress on MAR001 May 8, 2025
Marea Therapeutics presented positive data from the Phase 2a clinical trial of its fat-targeting monoclonal antibody, MAR001, that could help address lipid and metabolic drivers of ASCVD. To assess MAR001’s impact on remnant cholesterol and triglycerides, researchers randomized 55 patients with hypertriglyceridemia to one of three doses (150, 300, and 450mg) or placebo and found… […]
More Stories
Surgeries & Interventions May 5, 2025
FDA Approves TAVR for Asymptomatic AS May 5, 2025
TAVR will officially be an option for asymptomatic patients with severe aortic stenosis following the FDA’s approval of Edwards Lifesciences’ SAPIEN 3 platform for the patient group. EARLY TAVR was the first RCT designed to evaluate TAVR compared to watchful waiting for patients with asymptomatic severe AS. These results helped inform the FDA’s decision, but […]
Cardiology May 1, 2025
Cardiac Wire’s Top Six of HRS 2025 May 1, 2025
Heart Rhythm Society and sunny San Diego brought together the biggest HRS in years, with everything from custom presentation theaters to exciting afterparties. We hope everyone who attended HRS 2025 had as much fun as we did, and we hope all of you enjoy these top-six takeaways from electrophysiology’s biggest weekend of the year. HRS […]
Atrial Fibrillation April 28, 2025
GLP-1s Add AFib To Their Benefits List April 28, 2025
It seems like every week we’re discovering a new GLP-1 cardiac benefit, with the TRANSFORM-AF study now suggesting the drug could help reduce AFib burden. Examining the effects of GLP-1s on AFib, researchers examined 2.5k patients from 170 Veterans Affairs sites across the U.S. and found that AFib patients with obesity who were treated with […]
Surgeries & Interventions April 24, 2025
RESILIA’s Eight Year Results Impress for SAVR April 24, 2025
Eight-year data presented at HVS 2025 suggests that SAVR valves that use Edwards Lifesciences’ RESILIA tissue have better long-term outcomes compared to non-RESILIA bioprosthetic SAVR valves. The eight year data is the longest follow-up for valve tissue technology to date and comes from 947 patients in the COMMENCE and MAGNA EASE studies who received SAVR […]
Artificial Intelligence April 21, 2025
How AI is Expanding ECG and Echo’s Applications April 21, 2025
Building stronger evidence for AI’s place in cardiology, this week brought several examples of how AI can improve ECG use cases and automate Echo for new disease detection methods. Starting with AI improving ECG for coronary revascularization, a deep learning ECG model outperformed both clinician-led ECG and troponin T testing in predicting which ED patients […]
Cardiology Pharmaceuticals April 17, 2025
Verve Vaults Forward From Topline Results April 17, 2025
Completing its pharma comeback story, Verve Therapeutics announced successful results from the Heart-2 Phase 1b Clinical Trial of its in-vivo base editing drug, VERVE-102, that targets the PCSK9 gene for reducing LDL-C. VERVE-102’s topline results come from a small group of 14 patients across three different dose cohorts (weight-based cohorts of 0.3, 0.45, and 0.6mg/kg) […]
Cardiology Pharmaceuticals April 14, 2025
At Home Nasal Sprays and PSVT ER Visits April 14, 2025
Data analysis from the NODE-301 Phase 3 trial suggests that patients self-adminstering Milestone Pharmaceuticals’ etripamil (CARDAMYST) might be able to avoid ER visits for paroxysmal supraventricular tachycardia (PSVT). Sniffing around for proof of etripamil’s effectiveness, researchers analyzed data from parts 1 and 2 of the NODE-301 trial and found that patients who self-administered the drug […]
Cardiology Practices April 10, 2025
Does Value Based Care Improve Cardiology? April 10, 2025
Casting doubt on value based cardiac care, a JAMA study found that outpatient cardiology practices enrolled in an accountable care organization (ACO) through the Medicare Shared Savings Program (MSSP) don’t offer better care than non-ACO practices. Evaluating the ACO incentives, researchers compared care quality data from the ACC’s NCDR PINNACLE Registry before and 6-12 months […]
Atrial Fibrillation April 7, 2025
PFA or Cryoballoon for Paroxysmal AFib? April 7, 2025
Expanding the potential patient population for pulsed field ablation, results from the SINGLE SHOT CHAMPION study suggest PFA might be just as good as cryoballoon ablation for patients with paroxysmal AFib. In one of the first PFA versus cryoballoon head-to-heads, researchers randomized 210 patients with symptomatic paroxysmal AFib to undergo PFA with Boston Scientific’s Farapulse […]
Cardiology April 3, 2025
The Top Trends of ACC.25 April 3, 2025
The ACC 2025 meeting is all wrapped up after matching the attendance and excitement of last year’s expo, with a clear trend toward better diagnostics and even better pharmaceuticals. Among dozens of highlights, here are Cardiac Wire’s seven biggest trends from ACC.25. The Takeaway From software and hardware innovations in the exhibit hall to strong […]
Surgeries & Interventions March 31, 2025
Abbott Enters Burgeoning IVL Segment March 31, 2025
Intravascular lithotripsy (IVL) may have once been synonymous with Shockwave Medical, but it’s now rapidly becoming one of the hottest segments in interventional cardiology, spurred on by Abbott’s new IVL Investigational Device Exemption (IDE) from the FDA. Abbott’s new IVL IDE was two years in the making following its $890M acquisition of Cardiovascular Systems in 2023 […]
Cardiology Pharmaceuticals March 27, 2025
Ezetimibe Plus Statins Equals Better Outcomes March 27, 2025
New results from a vast Mayo Clinic meta-analysis suggest that combining ezetimibe with statins to lower LDL-C could have significant mortality and MACE benefits over statin monotherapy. Digging through decades of data from PubMed, Embase, and ClinicalTrials.gov, researchers pooled all relevant articles published through June 2024 (108k patients) and found that a combination lipid-lowering therapy […]
Cardiology Pharmaceuticals March 24, 2025
Amvuttra Arrives for ATTR-CM with a High Asking Price March 24, 2025
It’s not surprising that Alnylam’s Amvuttra (vutrisiran) received FDA approval for ATTR-CM last week, but what shocked many was Alnylam’s choice to price the drug at nearly half a million dollars per year in a segment where its incumbent competitors cost half as much. Alnylam claims Amvuttra’s eyewatering price stems from the drug’s “compelling and […]
Structural Heart March 20, 2025
Amulet’s Slight Edge over Watchman 2.5 for LAAO March 20, 2025
Although there’s still ongoing debate on who should receive LAAO devices, new five year results from the Amulet IDE trial confirm that both Abbott’s Amulet occluder and Boston Scientific’s Watchman 2.5 are safe and effective in the long run. Amulet IDE set Abbott’s contender against Boston Scientific’s Watchman 2.5 (its three generation old model), randomizing […]
Cardiology Pharmaceuticals March 17, 2025
Reconsidering LAAO Postprocedural Management March 17, 2025
Real-world data from the EMERGE LAA postapproval study suggests it might be time to rethink the discharge medications prescribed to patients after LAAO. Diving deeper into data from Abbott’s 11.5k patient EMERGE LAA postapproval study, researchers compared the adverse events and six month outcomes of single antiplatelet therapy (5.3% of patients), DAPT (81.7%), and oral […]
Surgeries & Interventions March 13, 2025
CABG Better than PCI for T2D Patients March 13, 2025
One of the biggest risk factors for patients who need coronary revascularization is diabetes, and a new study in JAMA suggests CABG could be a better option than FFR-guided PCI when it comes to long term outcomes for these patients. For a more nuanced head-to-head, researchers examined data from the FAME 3 trial for 428 […]
Surgeries & Interventions March 10, 2025
TAVR Long Term Outcomes Trump Surgery March 10, 2025
A new JACC study highlighted the long term benefits of TAVR using the Evolut valve (Medtronic) compared to surgical AVR when it comes to avoiding bioprosthetic valve dysfunction (BVD). Pitting data from the two techniques head-to-head, researchers examined 5.6k patients from the US High Risk Pivotal and SURTAVI randomized controlled trials, finding that TAVR patients […]
Cardiology Policy March 6, 2025
ABMS Rejects Independent CV Board, Doesn’t Explain Why March 6, 2025
In a move that could mark a serious setback for independent cardiology certification, the American Board of Medical Specialties (ABMS) denied the joint ACC/AHA/HRS/SCAI/HFSA request to launch a new American Board of Cardiovascular Medicine. Pushing for independence since 2023, the new American Board of Cardiovascular Medicine would have been completely independent of the ABIM and […]
